Simultaneous Radiotherapy with Continued use of Osimertinib in EGFR-mutated Adenocarcinomas of the Lung

被引：0
|
作者：
Syunyaeva, Z. [1 ,2 ]
Kauffmann-Guerrero, D. [3 ,4 ]
Kahnert, K. [5 ,6 ]
Behr, J. [7 ]
Tufman, A. [8 ,9 ]
机构：
[1] Klinikum Univ Munchen, Med Klin & Poliklin 5, Sekt Pneumol & Thorakale Onkol, Munich, Germany
[2] Lungentumorzentrum Munchen, Munich, Germany
[3] Univ Munich Lmu, Comprehens Pneumol Ctr, Dept Internal Med 5, Munich, Germany
[4] German Ctr Lung Res Dzl, Munich, Germany
[5] Ludwig Maximilians Univ Munchen, Dept Internal Med Resp Med & Thorac Oncol 5, Thorac Oncol Ctr Munich, Munich, Germany
[6] German Ctr Lung Res Dzl Cpc M, Munich, Germany
[7] Klinikum LMU Munchen, Med Klin & Poliklin 5, Comprehens Pneumol Ctr, Munich, Germany
[8] Ludwig Maximilian Univ Munich, Munich, Germany
[9] Ludwig Maximilian Univ Munich, Thorac Oncol Ctr, Div Resp Med & Thorac Oncol, Dept Internal Med 5, Munich, Germany
来源：
PNEUMOLOGIE | 2020年 / 74卷
关键词：
D O I：
10.1055/s-0039-3403365
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P527
引用
收藏
页码：S133 / S133
页数：1
相关论文
共 50 条
  • [41] Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Masahiro Tsuboi
    Roy S. Herbst
    Thomas John
    Terufumi Kato
    Margarita Majem
    Christian Grohé
    Jie Wang
    Jonathan W. Goldman
    Shun Lu
    Filippo de Marinis
    Frances A. Shepherd
    Ki Hyeong Lee
    Nhieu Thi Le
    Arunee Dechaphunkul
    Dariusz Kowalski
    Laura Bonanno
    Manuel Dómine
    Lynne Poole
    Ana Bolanos
    Yuri Rukazenkov
    Yi-Long Wu
    Targeted Oncology, 2024, 19 : 131 - 134
  • [42] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study
    Hu, Chunhong
    Wu, Sixuan
    Deng, Renfang
    Wu, Yuanqiang
    Pan, Yue
    Shu, Long
    Wu, Fang
    CANCER MEDICINE, 2023, 12 (01): : 266 - 273
  • [43] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [44] Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    John, Thomas
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu Thi
    Dechaphunkul, Arunee
    Kowalski, Dariusz
    Bonanno, Laura
    Domine, Manuel
    Poole, Lynne
    Bolanos, Ana
    Rukazenkov, Yuri
    Wu, Yi-Long
    TARGETED ONCOLOGY, 2024, 19 (02) : 131 - 134
  • [45] Osimertinib in Stage III EGFR-Mutated NSCLC - Game, Set, Match
    Leighl, Natasha B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (07): : 652 - 654
  • [46] MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Yan, D.
    Huelse, J.
    Parker, R.
    Wang, X.
    Frye, S.
    Earp, H. S.
    Deryckere, D.
    Graham, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1147 - S1147
  • [47] Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
    Leonetti, Alessandro
    Facchinetti, Francesco
    Tiseo, Marcello
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [48] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [49] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Fu, Kai
    Xie, Fachao
    Wang, Fang
    Fu, Liwu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [50] Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
    Kunimasa, Kei
    Kamada, Risa
    Oka, Toru
    Oboshi, Makiko
    Kimura, Madoka
    Inoue, Takako
    Tamiya, Motohiro
    Nishikawa, Tatsuya
    Yasui, Taku
    Shioyama, Wataru
    Nishino, Kazumi
    Imamura, Fumio
    Kumagai, Toru
    Fujita, Masashi
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 1 - 10
12345